Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Myelodysplastic Syndromes 1349Leukemia, Myeloid, Acute 1133Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Leukemia 675Precursor Cell Lymphoblastic Leukemia-Lymphoma 646Myeloproliferative Disorders 527Leukemia, Myelomonocytic, Chronic 424Lymphoma, Non-Hodgkin 407Primary Myelofibrosis 384Multiple Myeloma 369Leukemia, Lymphocytic, Chronic, B-Cell 367Hodgkin Disease 348Leukemia, Myeloid, Chronic-Phase 304Lymphoma 291Blast Crisis 256Leukemia, Myeloid, Accelerated Phase 238Lymphoma, Mantle-Cell 231Lymphoma, Follicular 226Burkitt Lymphoma 224Polycythemia Vera 222Lymphoma, Large B-Cell, Diffuse 219Lymphoma, B-Cell, Marginal Zone 203Congenital Abnormalities 192Anemia, Refractory, with Excess of Blasts 187Lymphoma, Large-Cell, Immunoblastic 182Myelodysplastic-Myeloproliferative Diseases 175Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 173Thrombocythemia, Essential 167Neoplasms, Plasma Cell 161Hematologic Neoplasms 161

Interventions

masitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Blushing × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡